We have constructed a novel and exclusively unique signal activation domain element Ori. After being inserted into the Next Generation CAR structure, it can increase the expansion efficiency of memory immune cells by several folds, effectively breaking through the physical barriers of the extracellular matrix in TME, resisting the immunosuppressive tumor microenvironment, significantly enhancing the anti-tumor activity and durability of CAR T-cells in vivo, and preventing recurrence. In addition, low-dose administration is allowed for CAR T-cell therapy involving a high proportion of memory T cells, which further reduces the safety risk caused by the drug itself.

We have achieved full application of the automated closed-type production process, which effectively reduces the production and preparation costs and improves the affordability of the medications for patients.